TG Therapeutics
TGTX
355 hedge funds and large institutions have $3.58B invested in TG Therapeutics in 2025 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 102 increasing their positions, 136 reducing their positions, and 48 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
1% less funds holding
Funds holding: 357 → 355 (-2)
2% less call options, than puts
Call options by funds: $80.5M | Put options by funds: $82M
2% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 48
1.62% less ownership
Funds ownership: 64.03% → 62.41% (-1.6%)
25% less repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 136
26% less capital inflows, than outflows
Capital inflows: $322M | Capital outflows: $434M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$52.7M |
| 2 |
ClearBridge Investments
New York
|
+$52.4M |
| 3 |
Man Group
London,
United Kingdom
|
+$28.6M |
| 4 |
Squarepoint
New York
|
+$16.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$38.5M |
| 2 |
Driehaus Capital Management
Chicago,
Illinois
|
-$29.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.7M |
| 4 |
Woodline Partners
San Francisco,
California
|
-$21.4M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$20.1M |
TGTX Hedge Fund Activity: Q3 2025 in Review
355 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2025, worth a combined $3.58B — down 2% from $3.65B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of TGTX and 47 opened new positions — a net loss of 1 holder — while 136 trimmed existing stakes and 102 added.
The largest buyer was Soleus Capital Management, adding an estimated $52.7M. The largest seller was Wellington Management Group, cutting an estimated $38.5M.
- 355 institutional investors held TG Therapeutics (TGTX) as of Q3 2025, down from 357 in Q2 2025.
- Funds reported $3.58B of TG Therapeutics stock for Q3 2025, down 2% quarter-over-quarter.
- 47 funds opened new TG Therapeutics positions in Q3 2025 and 48 closed out, a net change of -1 holder.
- The largest TG Therapeutics buyer in Q3 2025 was Soleus Capital Management, an estimated $52.7M added.
- The largest TG Therapeutics seller in Q3 2025 was Wellington Management Group, an estimated $38.5M sold.
Based on aggregated 13F filings for Q3 2025.